5267-34-5

Basic information

• Product Name: Aminodiphenylmethane hydrochloride
• Synonyms: PHENYLBENZENEMETHANAMINE HYDROCHLORIDE;LABOTEST-BB LT00159614;BENZHYDRYLAMINE HYDROCHLORIDE;ALPHA-AMINODIPHENYLMETHANE HYDROCHLORIDE;AMINODIPHENYLMETHANE HCL;AMINODIPHENYLMETHANE HYDROCHLORIDE;1,1-DIPHENYLMETHYLAMINE HYDROCHLORIDE;benzhydrylammonium chloride
• CAS NO: 5267-34-5
• Molecular Formula: C₁₃H₁₃N*ClH
• Molecular Weight: 219.71
• EINECS: 226-084-0
• Product Categories: Amine Salts;Building Blocks;Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks
• Mol File: 5267-34-5.mol

Chemical Properties

• Melting Point: 293-295 °C(lit.)
• Boiling Point: 301.1 °C at 760 mmHg
• Flash Point: 141.8 °C
• Appearance: white to off-white crystalline powder
• Density: 1.057 g/cm³
• Vapor Pressure: 0.00108mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Sensitive: Hygroscopic
• Merck: 14,1076
• BRN: 3914818
• CAS DataBase Reference: Aminodiphenylmethane hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Aminodiphenylmethane hydrochloride(5267-34-5)
• EPA Substance Registry System: Aminodiphenylmethane hydrochloride(5267-34-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 5267-34-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Aminodiphenylmethane hydrochloride is used as a molecular tool for blocking the maturation of nuclear lamin A, which plays a crucial role in the structural integrity of the cell nucleus. By inhibiting this process, it can help in decelerating cancer cell migration, thus providing a potential therapeutic approach in the treatment of cancer.
Used in Biotechnology Industry:
In the biotechnology sector, Aminodiphenylmethane hydrochloride can be utilized as a component in the development of novel drug delivery systems. Its unique properties may allow for the enhancement of drug targeting, improving the bioavailability and therapeutic outcomes of various pharmaceutical compounds.
Additionally, given its chemical properties and potential applications, Aminodiphenylmethane hydrochloride may also find use in other industries such as materials science for the development of new materials with specific properties, or in the chemical industry for the synthesis of other valuable compounds. However, further research and development would be necessary to explore these possibilities fully.

InChI:InChI=1/C13H13N.ClH/c14-13(11-7-3-1-4-8-11)12-9-5-2-6-10-12;/h1-10,13H,14H2;1H

Upstream product

• 101-81-5 Diphenylmethane 
• 6744-65-6 N-benzhydrylformamide 
• 100-46-9 benzylamine 
• 108-86-1 bromobenzene 
• 7699-79-8 benzhydrylidene-benzyl-amine 
• 5350-59-4 benzophenone N-benzhydrylimine 
• 574-66-3 Benzophenone oxime 
• 119-61-9 benzophenone 
• 91-00-9 Benzhydrylamine 
• 142310-26-7 1-<(diphenylmethylene)amino>-3-phenyl-4-methyl-5-methoxypyrazole 

Downstream Products

• 20922-69-4 N-diphenylmethyl-N'-triphenylmethyl urea 
• 6744-64-5 N,N'-dibenzhydryl-urea 
• 91-00-9 Benzhydrylamine 
• 54220-18-7 N-furfurylidene-1,1-diphenylmethylamine 
• 62506-88-1 N-benzylidenediphenylmethanamine 
• 189130-37-8 N-butylidene-1,1-diphenylmethanimine 
• 56542-90-6 N-(furan-2-ylmethyl)-1,1-diphenylmethanimine 
• 16766-99-7 α-phenylbenzylidene-n-butylamine 
• 18985-99-4 cyclohexylidene-N-(diphenylmethyl)amine 
• 16770-34-6 N-(α-phenylbenzylidene)cyclohexylamine 
• 29412-58-6 N-(diphenylmethyl)-1-phenylethan-1-imine 
• 64999-34-4 1,1-diphenyl-N-(1-phenylethyl)methanimine 
• 36735-58-7 N-(diphenylmethylidene)-N-(2-phenylethyl)amine 
• 51411-25-7 Benzophenon-propylimid 

Relevant articles and documents

Synthesis of α-Substituted Primary Benzylamines through Copper-Catalyzed Cross-Dehydrogenative Coupling

A copper-catalyzed route to α-substituted, primary benzylamines by C-H functionalization of alkylarenes is described. The method directly affords the amine hydrochloride salt. Catalyst loadings down to 0.1 mol % in combination with scalability, insensitivity to air and moisture, and no need for column chromatography makes the procedure highly practical. The facile synthesis of the racemate of a blockbuster drug highlights the relevance for the development of pharmaceuticals. Preliminary mechanistic data are also included.

Benzhydrylamine: An effective aminating agent for the synthesis of primary amines

Aldehydes, ketones, alkyl toluene-p-sulfonates and halides are converted into the corresponding primary amines with benzhydrylamine as a valuable ammonia synthon in moderate to excellent yields.

Preparation method of ethylamine benzhydrylamine

The invention provides a preparation method of azelnidipine starting material ethylamine benzhydrylamine. The method comprises the step of using benzophenone and formamide as raw materials to carry out aLeuckart reaction. The catalyst of silicon dioxide is added into a reaction system, and thus the reaction time is drastically reduced, wherein the time is decreased to 3-4 h from 8 h, and therefore energy consumption is significantly reduced; the rough product yield of a compound II is dramatically increased and is up to 96-98%. The purity of HPLC is not lower than 96.5%, so that it is ensured that after the ethylamine benzhydrylamine obtained by hydrochloric acid hydrolysis is purified once, the yield can reach 80%, the purity is not lower than 99.9%, and the ethylamine benzhydrylamine is quite suitable for industrial production.

APPLICATIONS OF N6-SUBSTITUTED ADENOSINE DERIVATIVE AND N6-SUBSTITUTED ADENINE DERIVATIVE TO CALMING, HYPNOSES, CONVULSION RESISTANCE, EPILEPTIC RESISTANCE, PARKINSON DISEASE RESISTANCE, AND DEMENTIA PREVENTION AND TREATMENT

PROBLEM TO BE SOLVED: To prepare analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. SOLUTION: The present invention relates to an N6-substituted adenosine derivative and an N6-substituted adenine derivative selected from the group consisting of specific compounds. The present invention also relates to a pharmaceutical composition at least comprising a therapeutically effective amount of the compounds and a pharmaceutically acceptable carrier. The invention further relates to the compounds used in preparation of analgesics, hypnotic agents, anticonvulsant agents, antiepileptics, antiparkinson drugs, dementia prophylactics, and health care food. COPYRIGHT: (C)2016,JPO&INPIT

Synthesis of diarylmethylamines via palladium-catalyzed regioselective arylation of 1,1,3-triaryl-2-azaallyl anions

Diarylmethylamines are of great interest due to their prevalence in pharmaceutical chemistry. As a result, new methods for their synthesis are in demand. Herein, we report a versatile protocol for the synthesis of diarylmethylamine derivatives involving palladium-catalyzed arylation of in situ generated 2-azaallyl anion intermediates. The 2-azaallyl anions are generated by reversible deprotonation of readily available aldimine and ketimine precursors. Importantly, the arylated aldimine and ketimine products do not undergo isomerization under the reaction conditions. Scale-up of the arylation and hydrolysis of the resulting products to furnish diarylmethylamines were also successfully performed. This journal is the Partner Organisations 2014.

N6-SUBSTITUTED ADENOSINE DERIVATIVES AND N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

N6-SUBSTITUTED ADENOSINE DERIVATIVES, N6-SUBSTITUTED ADENINE DERIVATIVES AND USES THEREOF

The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

Carbon-carbon bond formations at the benzylic positions of N-benzylxanthone imines and N-benzyldi-1-naphthyl ketone imine

Two N-benzyl imines are designed to allow for carbon-carbon bond formations at the aminated benzylic positions. Direct benzylic arylation reactions of N-benzylxanthone imine with aryl chlorides proceed under palladium catalysis in the presence of cesium hydroxide, yielding the corresponding benzhydrylamine derivatives. Alkylation reactions of N-benzyldi-1-naphthyl ketone imine with alkyl halides in the presence of potassium tert-butoxide afford the corresponding 1-phenylalkylamines in high yields. Conjugate addition of N-benzyldi-1-naphthyl ketone imine is also described.

Palladium-catalyzed benzylic arylation of N-benzylxanthone imine

(Chemical Equation Presented) The direct benzylic arylation of N-benzylxanthone imine with aryl chloride proceeds under palladium catalysis, yielding the corresponding coupling product. The product is readily transformed to benzhydrylamine. Taking into consideration that the imine is readily available from benzylic amine, the overall transformation represents a formal cross-coupling reaction of aryl halide with α-aminobenzyl metal.